Limited dissemination and shedding of the UL128 complex-intact, UL/b'-defective rhesus cytomegalovirus strain 180.92

Journal of Virology

Volumn 88, Issue 16, 2014, Pages 9310-9320

  Assaf, Basel T ^a,b,d   Mansfield, Keith G ^a   Strelow, Lisa ^b   Westmoreland, Susan V ^a   Barry, Peter A ^b,c   Kaur, Amitinder ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; COLON; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA EXTRACTION; EYE; HEART; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INOCULATION; KIDNEY; MACACA; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHESUS CYTOMEGALOVIRUS; SALIVA; TROPISM; UL B' GENE; UL128 COMPLEX; URINE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS DISSEMINATION; VIRUS EXCRETION; VIRUS GENE; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; WILD TYPE;

ANIMALS; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENDOTHELIUM; EPITHELIUM; FIBROBLASTS; HUMANS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; OPEN READING FRAMES; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL TROPISM; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84904876577     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00162-14     Document Type: Article

References (67)

1. Cannon MJ, Schmid DS, Hyde TB. 2010. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 20:202-213. http://dx.doi.org/10.1002/rmv.655.
2. Fields BN, Knipe DM, Howley PM. 2007. Fields virology, 5th ed. Wolters Kluwer Health/Lippincott/The Williams & Wilkins Co, Philadelphia, PA.
3. Yu D, Silva MC, Shenk T. 2003. Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proc. Natl. Acad. Sci. U. S. A. 100:12396-12401. http://dx.doi.org/10.1073/pnas.1635160100.
4. Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, Zhu H, Liu F. 2003. Functional profiling of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. U. S. A. 100:14223-14228. http://dx.doi.org/10.1073/pnas.2334032100.
5. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA, Hahn G, Nelson JA, Myers RM, Shenk TE. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 100:14976-14981. http://dx.doi.org/10.1073/pnas.2136652100.
6. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. 2004. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85:1301-1312. http://dx.doi.org/10.1099/vir.0.79888-0.
7. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70:78-83.
8. Weststrate MW, Geelen JL, Wertheim PM, van der Noordaa J. 1983. Comparison of the physical maps of the DNAs of two cytomegalovirus strains. J. Gen. Virol. 64(Pt 1):47-55.
9. Takekoshi M, Ihara S, Tanaka S, Maeda-Takekoshi F, Watanabe Y. 1987. A new human cytomegalovirus isolate has an invertible subsegment within its L component producing eight genome isomers. J. Gen. Virol. 68(Pt 3):765-776.
10. Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW. 2001. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev. Med. Virol. 11:191-200. http://dx.doi.org/10.1002/rmv.315.
11. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78:10023-10033. http://dx.doi.org/10.1128/JVI.78.18.10023-10033.2004.
12. Brown JM, Kaneshima H, Mocarski ES. 1995. Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. J. Infect. Dis. 171:1599-1603. http://dx.doi.org/10.1093/infdis/171.6.1599.
13. Gerna G, Percivalle E, Lilleri D, Lozza L, Fornara C, Hahn G, Baldanti F, Revello MG. 2005. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8 T cells. J. Gen. Virol. 86:275-284. http://dx.doi.org/10.1099/vir.0.80474-0.
14. Wang D, Shenk T. 2005. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. U. S. A. 102:18153-18158. http://dx.doi.org/10.1073/pnas.0509201102.
15. Sinzger C, Digel M, Jahn G. 2008. Cytomegalovirus cell tropism. Curr. Top. Microbiol. Immunol. 325:63-83. http://dx.doi.org/10.1007/978-3-540-77349-8_4.
16. Goodrum F, Reeves M, Sinclair J, High K, Shenk T. 2007. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110:937-945. http://dx.doi.org/10.1182/blood-2007-01-070078.
17. Umashankar M, Petrucelli A, Cicchini L, Caposio P, Kreklywich CN, Rak M, Bughio F, Goldman DC, Hamlin KL, Nelson JA, Fleming WH, Streblow DN, Goodrum F. 2011 A novel human cytomegalovirus locus modulates cell type-specific outcomes of infection. PLoS Pathog. 7:e1002444. http://dx.doi.org/10.1371/journal.ppat.1002444.
18. Spaderna S, Kropff B, Kodel Y, Shen S, Coley S, Lu S, Britt W, Mach M. 2005. Deletion of gpUL132, a structural component of human cytomegalovirus, results in impaired virus replication in fibroblasts. J. Virol. 79: 11837-11847. http://dx.doi.org/10.1128/JVI.79.18.11837-11847.2005.
19. Penfold ME, Dairaghi DJ, Duke GM, Saederup N, Mocarski ES, Kemble GW, Schall TJ. 1999. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. U. S. A. 96:9839-9844. http://dx.doi.org/10.1073/pnas.96.17.9839.
20. Poole E, King CA, Sinclair JH, Alcami A. 2006. The UL144 gene product of human cytomegalovirus activates NFκB via a TRAF6-dependent mechanism. EMBO J. 25:4390-4399. http://dx.doi.org/10.1038/sj.emboj.7601287.
21. Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR, Cochrane D, Moore M, Wilkinson GW, Tomasec P. 2010. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J. Gen. Virol. 91:2034-2039. http://dx.doi.org/10.1099/vir.0.021931-0.
22. Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG. 2005. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J. Immunol. 175:7457-7465. http://dx.doi.org/10.4049/jimmunol.175.11.7457.
23. Plotkin SA, Farquhar J, Horberger E. 1976. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J. Infect. Dis. 134:470-475. http://dx.doi.org/10.1093/infdis/134.5.470.
24. Elek SD, Stern H. 1974. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet i:1-5.
25. Quinnan GV, Jr, Delery M, Rook AH, Frederick WR, Epstein JS, Manischewitz JF, Jackson L, Ramsey KM, Mittal K, Plotkin SA, et al. 1984. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann. Intern. Med. 101: 478-483. http://dx.doi.org/10.7326/0003-4819-101-4-478.
26. Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF. 1984. Townevaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet i:528-530.
27. Plotkin SA, Huang ES. 1985. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J. Infect. Dis. 152:395-397. http://dx.doi.org/10.1093/infdis/152.2.395.
28. Yue Y, Kaur A, Zhou SS, Barry PA. 2006. Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65). J. Gen. Virol. 87:777-787. http://dx.doi.org/10.1099/vir.0.81516-0.
29. Lilja AE, Chang WL, Barry PA, Becerra SP, Shenk TE. 2008. Functional genetic analysis of rhesus cytomegalovirus: Rh01 is an epithelial cell tropism factor. J. Virol. 82:2170-2181. http://dx.doi.org/10.1128/JVI.02316-07.
30. Oxford KL, Eberhardt MK, Yang KW, Strelow L, Kelly S, Zhou SS, Barry PA. 2008. Protein coding content of the UL/b= region of wild-type rhesus cytomegalovirus. Virology 373:181-188. http://dx.doi.org/10.1016/j.virol.2007.10.040.
31. Hansen SG, Strelow LI, Franchi DC, Anders DG, Wong SW. 2003. Complete sequence and genomic analysis of rhesus cytomegalovirus. J. Virol. 77: 6620-6636. http://dx.doi.org/10.1128/JVI.77.12.6620-6636.2003.
32. Oxford KL, Strelow L, Yue Y, Chang WL, Schmidt KA, Diamond DJ, Barry PA. 2011. Open reading frames carried on UL/b= are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys. J. Virol. 85:5105-5114. http://dx.doi.org/10.1128/JVI.02631-10.
33. Rivailler P, Kaur A, Johnson RP, Wang F. 2006. Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus. J. Virol. 80:4179-4182. http://dx.doi.org/10.1128/JVI.80.8.4179-4182.2006.
34. Bowman JJ, Lacayo JC, Burbelo P, Fischer ER, Cohen JI. 2011. Rhesus and human cytomegalovirus glycoprotein L are required for infection and cell-to-cell spread of virus but cannot complement each other. J. Virol. 85:2089-2099. http://dx.doi.org/10.1128/JVI.01970-10.
35. Yue Y, Barry PA. 2008. Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus. Adv. Virus Res. 72:207-226. http://dx.doi.org/10.1016/S0065-3527(08)00405-3.
36. Baroncelli S, Barry PA, Capitanio JP, Lerche NW, Otsyula M, Mendoza SP. 1997. Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15:5-15. http://dx.doi.org/10.1097/00042560-199705010-00002.
37. Sequar G, Britt WJ, Lakeman FD, Lockridge KM, Tarara RP, Canfield DR, Zhou SS, Gardner MB, Barry PA. 2002. Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis. J. Virol. 76:7661-7671. http://dx.doi.org/10.1128/JVI.76.15.7661-7671.2002.
38. Lockridge KM, Sequar G, Zhou SS, Yue Y, Mandell CP, Barry PA. 1999. Pathogenesis of experimental rhesus cytomegalovirus infection. J. Virol. 73:9576-9583.
39. Kaur A, Daniel MD, Hempel D, Lee-Parritz D, Hirsch MS, Johnson RP. 1996. Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J. Virol. 70:7725-7733.
40. Kaur A, Hale CL, Noren B, Kassis N, Simon MA, Johnson RP. 2002. Decreased frequency of cytomegalovirus (CMV)-specific CD4 T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia. J. Virol. 76:3646-3658. http://dx.doi.org/10.1128/JVI.76.8.3646-3658.2002.
41. Kaur A, Kassis N, Hale CL, Simon M, Elliott M, Gomez-Yafal A, Lifson JD, Desrosiers RC, Wang F, Barry P, Mach M, Johnson RP. 2003. Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J. Virol. 77:5749-5758. http://dx.doi.org/10.1128/JVI.77.10.5749-5758.2003.
42. Asher DM, Gibbs CJ, Jr, Lang DJ, Gajdusek DC, Chanock RM. 1974. Persistent shedding of cytomegalovirus in the urine of healthy rhesus monkeys. Proc. Soc. Exp. Biol. Med. 145:794-801. http://dx.doi.org/10.3181/00379727-145-37897.
43. Lilja AE, Shenk T. 2008. Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proc. Natl. Acad. Sci. U. S. A. 105:19950-19955. http://dx.doi.org/10.1073/pnas.0811063106.
44. Patrone M, Secchi M, Fiorina L, Ierardi M, Milanesi G, Gallina A. 2005. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J. Virol. 79:8361-8373. http://dx.doi.org/10.1128/JVI.79.13.8361-8373.2005.
45. Wang D, Shenk T. 2005. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 79:10330-10338. http://dx.doi.org/10.1128/JVI.79.16.10330-10338.2005.
46. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U. 2006. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J. Gen. Virol. 87:2451-2460. http://dx.doi.org/10.1099/vir.0.81921-0.
47. Assaf BT, Mansfield KG, Westmoreland SV, Kaur A, Oxford KL, Diamond DJ, Barry PA. 2012. Patterns of acute rhesus cytomegalovirus (RhCMV) infection predict long-term RhCMV infection. J. Virol. 86: 6354-6357. http://dx.doi.org/10.1128/JVI.00607-12.
48. Barry PA, Alcendor DJ, Power MD, Kerr H, Luciw PA. 1996. Nucleotide sequence and molecular analysis of the rhesus cytomegalovirus immediate-early gene and the UL121-117 open reading frames. Virology 215:61-72. http://dx.doi.org/10.1006/viro.1996.0007.
49. Alcendor DJ, Barry PA, Pratt-Lowe E, Luciw PA. 1993. Analysis of the rhesus cytomegalovirus immediate-early gene promoter. Virology 194: 815-821. http://dx.doi.org/10.1006/viro.1993.1323.
50. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G. 2004. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin. Infect. Dis. 39:155-161. http://dx.doi.org/10.1086/421496.
51. Puchhammer-Stockl E, Gorzer I, Zoufaly A, Jaksch P, Bauer CC, Klepetko W, Popow-Kraupp T. 2006. Emergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients. Transplantation 81:187-194. http://dx.doi.org/10.1097/01.tp.0000194858.50812.cb.
52. Rasmussen L, Geissler A, Winters M. 2003. Inter-and intragenic variations complicate the molecular epidemiology of human cytomegalovirus. J. Infect. Dis. 187:809-819. http://dx.doi.org/10.1086/367900.
53. Just M, Buergin-Wolff A, Emoedi G, Hernandez R. 1975. Immunization trials with live attenuated cytomegalovirus TOWNE 125. Infection 3:111-114. http://dx.doi.org/10.1007/BF01641052.
54. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE. 1989. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis. 159:860-865. http://dx.doi.org/10.1093/infdis/159.5.860.
55. Fleisher GR, Starr SE, Friedman HM, Plotkin SA. 1982. Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am. J. Dis. Child. 136:294-296.
56. Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ, McGeoch DJ, Hayward GS. 2003. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J. Gen. Virol. 84:17-28. http://dx.doi.org/10.1099/vir.0.18606-0.
57. Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemcovicova I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA. 2013. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe 13:324-335. http://dx.doi.org/10.1016/j.chom.2013.02.003.
58. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, McSharry BP, Morris RJ, Llewellyn-Lacey S, Rickards C, Nomoto A, Sinzger C, Wilkinson GW. 2005. Downregulation of natural killer cellactivating ligand CD155 by human cytomegalovirus UL141. Nat. Immunol. 6:181-188. http://dx.doi.org/10.1038/ni1156.
59. Benedict CA, Butrovich KD, Lurain NS, Corbeil J, Rooney I, Schneider P, Tschopp J, Ware CF. 1999. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J. Immunol. 162:6967-6970.
60. Cheung TC, Humphreys IR, Potter KG, Norris PS, Shumway HM, Tran BR, Patterson G, Jean-Jacques R, Yoon M, Spear PG, Murphy KM, Lurain NS, Benedict CA, Ware CF. 2005. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc. Natl. Acad. Sci. U. S. A. 102:13218-13223. http://dx.doi.org/10.1073/pnas.0506172102.
61. Poole E, Walther A, Raven K, Benedict CA, Mason GM, Sinclair J. 2013. The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner. J. Virol. 87:4261-4271. http://dx.doi.org/10.1128/JVI.03497-12.
62. Baskin GB. 1987. Disseminated cytomegalovirus infection in immunodeficient rhesus monkeys. Am. J. Pathol. 129:345-352.
63. Jabs DA. 1995. Ocular manifestations of HIV infection. Trans. Am. Ophthalmol. Soc. 93:623-683.
64. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. 1992. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 5:1069-1074.
65. Rasmussen L. 1999. Molecular pathogenesis of human cytomegalovirus infection. Transpl. Infect. Dis. 1:127-134. http://dx.doi.org/10.1034/j.1399-3062.1999.010206.x.
66. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. 2011. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256-1263. http://dx.doi.org/10.1016/S0140-6736(11)60136-0.
67. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360:1191-1199. http://dx.doi.org/10.1056/NEJMoa0804749.